Valiant Organics Ltd
Valiant Organics Ltd Q4 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book
Q4 FY25 investor presentation: what the company reported on revenue, margins and projects.
Based on Valiant Organics Ltd's Q4 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10). Q4 FY25 Consolidated Financials (Page 12 & 9): - EBITDA: INR 203 Mn, up from INR (18) Mn in Q4 FY24 (YoY positive turnaround) - EBITDA Margin: 9.96%, improved from -1.02% in Q4 FY24 (YoY improvement of 1,098 bps) - PAT: INR 42 Mn, up from INR (202) Mn in Q4 FY24 (significant YoY recovery) - PAT Margin: 2.06%, versus -11.43% in Q4 FY24 (YoY positive turnaround) - EPS (Basic/Diluted): INR 1.52/share, compared to (3.81) in Q4 FY24 - Explicit Margin Outlook: - The presentation does not explicitly state any forward-looking margin guidance or outlook (Page 23 Disclaimer clarifies no obligation to update forward-looking statements).
From Valiant Organics Ltd's Q4 FY25 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10).
- Key chemistries sales volumes (MT) for Q4-FY25:
- Chlorination: 379 MT (up from 360 MT in Q4-FY24)
- Hydrogenation: 1,126 MT (up from 879 MT in Q4-FY24)
- Ammonolysis: 458 MT (down from 513 MT in Q4-FY24) (Page 11)
- Q4-FY25 revenue performance driven by higher volumes and improved realizations across key segments (Page 10).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Valiant Organics Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Chemicals & Petrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Valiant Organics Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Valiant Organics Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹218 Cr, net profit ₹15 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Valiant Organics Ltd's management said in earlier quarters
- Q2 FY25 earnings call analysis →
- Q4 FY24 earnings call analysis →
- Q1 FY25 earnings call analysis →
- Q3 FY25 earnings call analysis →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
- Q4 FY23 earnings call →
- Q3 FY23 earnings call →
- Q2 FY23 earnings call →
- Q1 FY23 earnings call →
- Q4 FY22 earnings call →
Others in Chemicals & Petrochemicals this season
- Atul Ltd (Q4 FY25)
Consolidated revenue from operations for 2024-25: ₹5,583 cr, 18% increase YoY from ₹4,726 cr in 2023-24 (Page 36). Key investor presentation takeaways from Atul
- Vidhi Specialty Food Ingredients Ltd (Q4 FY25)
109.5 Crs, up 40.2% YoY (from Rs. Key investor presentation takeaways from Vidhi Specialty Food Ingredients Ltd's Q4 FY25 investor presentation — and how it ran
- Chemcon Speciality Chemicals Ltd (Q4 FY25)
54.9 Crs, down 8% YoY from Rs. Key investor presentation takeaways from Chemcon Speciality Chemicals Ltd's Q4 FY25 investor presentation — and how it ranks agai
- Clean Science (Q4 FY25)
2,500 crores to Rs. Key concall takeaways from Clean Science's Q4 FY25 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Valiant Organics Ltd Q4 FY25 results?
Q4-FY25 revenue from operations (consolidated) was INR 2,038 million, a 15.3% year-on-year (YoY) increase from INR 1,768 million in Q4-FY24 (Page 12 and 10). Q4 FY25 Consolidated Financials (Page 12 & 9): - EBITDA: INR 203 Mn, up from INR (18) Mn in Q4 FY24 (YoY positive turnaround) - EBITDA Margin: 9.96%, improved from -1.02% in Q4 FY24 (YoY improvement of 1,098 bps) - PAT: INR 42 Mn, up from INR (202) Mn in Q4 FY24 (significant YoY recovery) - PAT Margin: 2.06%, versus -11.43% in Q4 FY24 (YoY positive turnaround) - EPS (Basic/Diluted): INR 1.52/share, compared to (3.81) in Q4 FY24 - Explicit Margin Outlook: - The presentation does not explicitly state any forward-looking margin guidance or outlook (Page 23 Disclaimer clarifies no obligation to update forward-looking statements).
What is Valiant Organics Ltd share price analysis?
Valiant Organics Ltd currently shows a neutral. The stock trades at a P/E of 23.7 with a market cap of ₹1,196 Cr. Investors should review the full earnings analysis for detailed insights.
Is Valiant Organics Ltd planning capital expenditure?
The investor presentation contains no explicit information about capex, capacity expansion, or new plants/projects including amounts, status, or timelines.
Keep Valiant Organics Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.